Medicus Pharma (MDCX) Short term Debt (2025)

Medicus Pharma (MDCX) posted Short term Debt of $5.2 million for Q4 2025, down 22.7% quarter-over-quarter from $6.8 million in Q3 2025.

Medicus Pharma (MDCX) Short term Debt (2025) Analysis & Trends

Medicus Pharma (MDCX) has reported Short term Debt for 1 consecutive years, with $5.2 million the latest figure, recorded in Q4 2025.

Short term Debt for Q4 2025 came in at $5.2 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $5.2 million (changed N/A YoY), and the FY2025 annual result was $5.2 million, changed N/A from the prior year.
Short term Debt was $5.2 million for Q4 2025 at Medicus Pharma, down from $6.8 million in the prior quarter.
Over five years, Short term Debt peaked at $6.8 million in Q3 2025 and troughed at $4.7 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-
10	Medicus Pharma	6.91 Mn	-1.69 Mn	-

Download Data